Skip to content
#protein folding Open access

BTK/BCL2 dual targeting enhances apoptosis in marginal zone lymphoma: preclinical activity of tacabrutideg (BGB-16673) and sonrotoclax.

Oct 2026 · Haematologica · 0 citations · 20 references
Medicine

TL;DR

Tacabrutideg demonstrates potent preclinical activity in MZL as a single agent and in combination regimens, and together with the superior activity of sonrotoclax, these findings provide a strong rationale for the clinical evaluation of dual BTK degradation and BCL2 inhibition in patients with MZL.

Abstract

Bruton tyrosine kinase (BTK) and BCL2 are key therapeutic targets in marginal zone lymphoma (MZL). We evaluated the novel BTK degrader tacabrutideg (BGB-16673) and the secondgeneration BCL2 inhibitor sonrotoclax, alone and in combination, in MZL models, including derivatives with acquired resistance to BTK, BCL2, and PI3K inhibitors. Tacabrutideg was evaluated for cytotoxicity, apoptosis, transcriptomic and protein changes, real-time cell growth, three-dimensional stromal co-culture, and activity in primary MZL samples. Combination studies included sonrotoclax, venetoclax, bendamustine, lenalidomide, rituximab, selinexor, and tazemetostat.Tacabrutideg showed single-agent activity in MZL cell lines, inducing BTK degradation and suppression of BCR signaling, MYC targets, and oxidative phosphorylation. Its biological effects largely overlapped with those of zanubrutinib while maintaining complete target degradation. Tacabrutideg inhibited PLCG2 and ERK phosphorylation, reduced cell growth in realtime assays, retained activity in three-dimensional stromal co-cultures, and suppressed growth and ERK phosphorylation in primary MZL samples. Combination studies identified the greatest benefit with sonrotoclax, venetoclax, bendamustine, lenalidomide, and rituximab. Sonrotoclax consistently outperformed venetoclax, exhibiting >10-fold greater potency in three MZL cell lines and synergizing with tacabrutideg across multiple models. The combination enhanced apoptosis through coordinated modulation of BCL2 family proteins, including BCL2, MCL1, and BCL-XL. Tacabrutideg demonstrates potent preclinical activity in MZL as a single agent and in combination regimens. Together with the superior activity of sonrotoclax, these findings provide a strong rationale for the clinical evaluation of dual BTK degradation and BCL2 inhibition in patients with MZL.

Read PDF

Similar papers

Sep 2026

Abstract B012: In vivo Mini screen to assess the Antitumor Effect of Carboxyamidotriazole orotate (CTO) and temozolomide (TMZ) in Monotherapy in Three ITCC-P4’s High-grade Glioma (HGG) Pediatric Patient Derived Xenograft (PDX) Tumor Models

The aim of this study was to evaluate in vivo antitumor activity of CTO, a novel, oral small molecule orotate formulation of carboxyamidotriazole (CAI). The antiproliferative and antimetastatic properties of CTO are driven by the inhibition of calcium influx through receptor-operated channels. By disrupting calci...

R. Karmali, Romina Walter, J. Gojo et al. · 0 citations
Open access Sep 2026

Gene expression analysis after BTK and PI3Kδ inhibitor treatment in chronic lymphocytic leukemia identifies cell‐surface CXCR4 as a synergistic target for combinatorial therapy

BTKi are preferred in clinical practice over idelalisib due to lower toxicity, but idelalisib plus anti ‐ CD20 antibodies remains relevant in the treatment of CLL cases resistant to BTKi and vene-toclax, in BTKi ‐ intolerant patients, and next ‐ generation PI3Ki such as duvelisib or umbralisib are being developed.

Gabriela Mladonicka Pavlasova, Veronika Šandová, L. Ondrišová et al. · 0 citations
Open access Oct 2026

Baicalein Synergizes with Docetaxel in TNBC and the Combination Suppresses AKT/GSK3β/β-Catenin Signaling

Limited docetaxel efficacy in triple-negative breast cancer (TNBC) necessitates chemosensitizers. Baicalein is a potential chemosensitizer, but its synergy with docetaxel in TNBC is unclear. Here, we investigated the combined effects and underlying mechanisms. The concentrations of baicalein (80 μM) and docetaxel (20 n...

Tao-Mei Yang, Xiang-Yun Chen, Chun-Wei Chu et al. · 0 citations
Oct 2026

Acute MCL1 Loss via Homoharringtonine-Mediated Translational Inhibition Enables Potent Apoptotic Synergy with BCLXL Blockade.

Antiapoptotic buffering in solid tumors is generally mediated by both BCLXL and MCL1, so that BH3 mimetic drugs targeting only one have limited efficacy. To identify agents that may sensitize tumors to BH3 mimetics targeting BCLXL, we screened prostate cancer cells against a panel of mitochondria-targeted drugs in comb...

Akira Ohtsu, Tatsuhiro Sawada, L. Poluben et al. · 0 citations
Oct 2026

Discovery of Tricyclic Oxazinoquinolinone-Based BCL6 PROTAC Degraders with Potent Activity Against Diffuse Large B-Cell Lymphoma

Overall, compound 15 represents a promising BCL6 PROTAC degrader for DLBCL, which induced rapid and efficient BCL6 degradation in OCI-LY1 cells and displayed potent antiproliferative activity in BCL6-dependent DLBCL cells.

Xue-Tao Chen, Ru-Ju Xu, Xiao-Ran Wang et al. · 0 citations
Open access Oct 2026

Triterpenoid Exposure and HO-1 Blockade Sensitize Neoplastic Mast Cells Against Midostaurin and Avapritinib

Advanced systemic mastocytosis (advSM), including aggressive SM (ASM), SM with an associated hematologic neoplasm (SM-AHN) and mast cell leukemia (MCL), are rare, mostly KIT D816V-driven malignancies with a poor prognosis. KIT D816V-targeting drugs, such as midostaurin or avapritinib, can induce hematologic responses i...

Max Vincent John, Yüksel Filik Schüppler, Nadine Witzeneder et al. · 0 citations

Related blog posts

Google DeepMind Blog Sep 30, 2026

Introducing SynthID Bio

Proof of concept for watermarking AI-generated proteins while preserving biological function.

MIT News · Artificial Intelligence Aug 27, 2026

Looking beyond natural sequences

A new machine-learning framework aims to improve the success rate of computational protein design while moving away from results that reproduce sequences found in nature.

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.